Drug Information

Drug General Information
Drug ID
D0I3YX
Former ID
DNCL001889
Drug Name
Capadenoson
Drug Type
Small molecular drug
Indication Atrial fibrillation [ICD9: 272, 427.31; ICD10:E78, I48] Phase 2 [522175]
Company
Bayer HealthCare Pharmaceuticals
Formula
C25H18ClN5O2S2
PubChem Compound ID
9936489
Target and Pathway
Target(s) Adenosine A1 receptor Target Info Agonist [529810]
KEGG Pathway cGMP-PKG signaling pathway
cAMP signaling pathway
Sphingolipid signaling pathway
Neuroactive ligand-receptor interaction
Morphine addiction
NetPath Pathway TCR Signaling Pathway
RANKL Signaling Pathway
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Reactome Adenosine P1 receptors
G alpha (i) signalling events
WikiPathways Nucleotide GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 522175ClinicalTrials.gov (NCT00568945) Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.. U.S. National Institutes of Health.
Ref 529810A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.